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Background: The investigation of glycated hemoglobin (HbA1c) as a diagnostic tool for abnormal
glycometabolism is lack in acute ischemic stroke patients in China and worldwide. This paper was aimed to
determine whether HbA1c, fasting plasma glucose (FPG), or HbA1c combined with FPG, could be used to
screen for diabetes mellitus (DM) or prediabetes in acute ischemic stroke patients without previous DM.
Methods: Acute ischemic stroke patients without previous DM (n = 1,316) were selected from the Abnormal
gluCose Regulation in Patients with Acute StrOke acrosS China Study (ACROSS-China). Oral glucose tolerance
test (OGTT), HbA1c, FPG, and HbA1c combined with FPG were used as the screening methods to categorize the
glycometabolic status. OGTT was taken as the golden method. Venn diagrams and the overlap index were used
to determine the associations among the three methods of identifying abnormal glycometabolism. The area under
the receiver operating characteristic curve (AUROC) and Youden index were used to assess and compare the
accuracy in detecting abnormal glycometabolism. Youden analyses were performed to determine the ideal cutoff
values of HbA1c in diagnosing abnormal glycometabolism.
Results: In acute ischemic stroke patients without previous DM, the overlaps of HbA1c versus OGTT, HbA1c versus
FPG, and all the three methods independently, were low for detecting abnormal glycometabolism (all <50%).
HbA1c can significantly detect more cases of prediabetes than OGTT (P < 0.001). The combination of HbA1c and
FPG significantly raised the sensitivity to over 60.0%, specificity to over 80.0%, and the diagnostic accuracy
(Youden index from under 40.0% to 42.4%)for DM. HbA1c of 5.7%-6.4% had a low to moderate concordance
with OGTT for identifying prediabetes (AUROC = 0.557, P = 0.001). HbA1c values of 6.3% and 5.9% were found to
be the ideal cutoff values for detecting DM and abnormal glycometabolism in our data, respectively.
Conclusions: The combination of HbA1c and FPG increased the diagnostic rate of DM when compared with OGTT,
and increased the diagnostic accuracy for DM compared with HbA1c or FPG alone. Our results advocate the use of
HbA1c as screening tool for the diagnosis of pre-diabetes.
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Glycated hemoglobin (HbA1c) can be indicative of the
average glucose level of the preceding 2–3 months. HbA1c
is an easy method to screen for diabetes mellitus (DM) but
compared to oral glucose tolerance test (OGTT), its sensi-
tivity for detecting DM is low. However, the American
Diabetes Association (ADA) endorses the use of HbA1C
based on its familiarity to clinicians, simple manipulation,
and no need to fast. Meanwhile, an HbA1c level of
5.7-6.4% was recommended as the diagnostic criterion
for prediabetes due to a high risk for developing DM from
the patients with this HbA1c level [1,2].
The test of fasting plasma glucose (FPG) requires no
caloric intake for at least eight hours. FPG has been typ-
ically used to monitor the glucose status of patients in
clinics or hospitals. The benefits of using FPG include
its simplicity of use, low cost, and ease of interpretation.
However, its results are easily influenced by fluctuations
in glucose level [3].
According to the World Health Organization (WHO)
criteria in 1997, OGTT is one method to diagnose ab-
normal glucose levels. OGTT following an overnight fast
for at least eight hours was performed via an oral intake
of a standard dose of 75 g anhydrous glucose dissolved
in water. Fasting plasma glucose levels were measured
prior to administering the anhydrous glucose and post-
prandial glucose was evaluated two hours later. Patients
were not allowed or recommended to have a special diet
during the two hours. Fasting plasma glucose and 2-h
plasma glucose (PG2h) were used in combination to
diagnose DM or prediabetes [4,5].
Since a high prevalence of abnormal glycometabolism
diagnosed using OGTT among Chinese patients with
acute stroke has been estimated [6] and both DM and a
high ‘normal’ glycamia status are high risks for stroke
[7], there is a great need to find an efficient screening
test to identify abnormal glycometabolism in patients
with acute ischemic stroke. However, OGTT is limited
in the clinical practice because it is inconvenient, time-
consuming, relatively expensive, and requires the patient
to fast [3]. A method aside from OGTT is needed to diag-
nose abnormal glycometabolism quickly and easily.
Up to date, although several recent studies worldwide
have compared the ability of diagnosing abnormal glycome-
tabolism between OGTT and HbA1c with or without FPG
based on disease spectrums and patient populations [8-12],
the results were inconsistent and a similar study focus on
acute ischemic stroke patients was still lacking [13].
In the present study, we aimed to compare the diag-
nostic accuracy among HbA1c, FPG, and OGTT for
newly-diagnosed DM and pre-diabetes among patients
with acute ischemic stroke. An ideal cut-off value of
HbA1c was also pursued to better diagnose abnormal




Patients (n = 1,316) were selected from the ACROSS-
China study (n = 3,450) [6]. Patients were excluded suc-
cessively as below: subarachnoid hemorrhage (n = 162),
intracerebral hemorrhage (n = 649), previous diagnosis
of DM (n = 534), patients who declined OGTT (n = 312),
missing HbA1c value (n = 432), and missing FPG value
(n = 45). OGTT, HbA1c, FPG, and HbA1c combined with
FPG were used to categorize the glycometabolism status
in patients with acute ischemic stroke (Figure 1).
Diagnostic criteria and methods of abnormal
glycometabolism status
Blood samples were collected for the evaluation of FPG
and HbA1c within 24 hours after admission. OGTT was
done on the 14th day after stroke onset.
The WHO 1999 criteria for OGTT to identify DM,
prediabetes, an normoglycemia were as follows: 1) DM
defined as FPG ≥7.0 mmol/L and/or PG2h ≥11.1 mmol/L;
2) intermediate hyperglycaemia, which consists of impaired
glucose tolerance (IGT) (FPG <7.0 mmol/L and PG2h be-
tween 7.8 mmol/L and 11.1 mmol/L), and impaired fasting
glucose (IFG) (FPG between 6.1 mmol/L and 7.0 mmol/L,
and PG2h <7.8 mmol/L); and 3) normoglycemia defined as
FPG <6.1 mmol/L and a PG2h <7.8 mmol/L. All the pa-
tients were categorized into these three groups according
to OGTT results.
The FPG criteria for diagnosing glycometabolism
status were as follows: DM defined as ≥7.0 mmol/L,
prediabetes was defined as from 5.6 to 6.9 mmol/l [4,5].
Patients who had FPG of ≥7.0 mmol/L were required to
repeat FPG test on the next day. A diagnosis of DM
was made for a patient only when both FPG values
were ≥7.0 mmol/L. When the FPG value was ≥7.0 mmol/L
at the first time but 6.1 - 7.0 mmol/L at the second time, a
diagnosis of prediabetes was made. When the FPG value
was ≥7.0 mmol/L at the first time but <5.6 mmol/L
at the second time, normoglycaemia was diagnosed for
the patient.
The criteria of HbA1c were used to predict DM, predia-
betes, and normoglycemia were: HbA1c ≥6.5%, HbA1c5.7-
6.4%, and HbA1c <5.7% were used as the criteria for
diabetes, prediabetes, and normoglycemia [1,2].
The measurement methods of OGTT and HbA1c were
the same as described in previously published studies
[6,7]. The blood samples for HbA1c evaluation were
separated and the plasmas were properly processed, re-
frigerated at −20°C, and transported to Beijing Tiantan
Hospital in Beijing, China. The laboratory in Beijng Tiantan
Hospital was certified by the National Glycohemoglobin
Figure 1 Flow chart of patient selection.
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ment. HbA1c was measured using ‘high performance liquid
chromatographic analysis’ (HPLC) by a Bio-Rad Varian-
tIIanalyzer (Bio-Rad Laboratories, Hercules, CA) with a
reference value of 4.1-6.5% in accordance with the standard
in the Diabetes Control and Complications Trial (DCCT)
and NGSP. The intra-assay coefficient of variation (CV)
was 2.5% and the interassay CV was <4.0%, both of them
were within the limits of the NGSP.
Other variables
Clinical data from patients were obtained within 24 hours
after admission. Information included age, gender, smok-
ing status (current smoking was defined as an individual
who smoked at the time of stroke), alcohol intake (mod-
erate or severe drinking was defined as the consumption
of at least two standard alcoholic beverages per day), a
previous medical history, body mass index (BMI), blood
routine and biochemical indexes including blood cell
counts, hemoglobin, platelet counts, creatinine, triglycer-
ide, lipoprotein, and cholesterol levels.
Ethics statement
Procedures at all participating centers were approved by
the ethics committee at Beijing Tiantan Hospital. Written
informed consent was obtained from all patients, or from
their designated family members.
Statistical analysis
Clinical data of patients with ischemic stroke without
previous DM were compared. Study patients were sepa-
rated based on the new glycometabolic status according
to OGTT results. Continuous data and categorical data
were presented as mean ± standard deviation and fre-
quency/ratio, respectively. The variables were compared
through one-way analysis of variance, test χ2 or Fisher’sexact test. Detection rate of abnormal glycometabolism
diagnosis were calculated using various diagnostic
methods. Venn diagrams were used to illustrate the con-
cordances and variances among the three methods of
detecting the abnormal glycometabolism. The overlap
index was calculated as the event number of concordant
diagnoses divided by the event number diagnosed by
either HbA1c or FPG, either HbA1c or OGTT, and
either HbA1c or FPG or OGTT, which reflected the
agreements among the three methods. An overlap index
value of lower than 50% was considered poor agreement.
The receiver operating characteristic curve was used to
calculate the area under the receiver operating character-
istic curve (AUROC), sensitivity, and specificity. OGTT
was taken as the golden method in AUROC analysis.
Youden indexes (maximum values of sensitivity plus
specificity minus one) of the three tests were compared
for diagnostic accuracy of identifying abnormal glycome-
tabolism. Youden analysis was done to discover an ideal
cut-off value of HbA1c for diagnosing abnormal glycome-
tabolism status in our data. Because both HbA1c and FPG
tests were taken in the same set of subjects, the AUROCs
of the two tests we got were not independent. The com-
parisons between the AUROCs were performed by using
the nonparametric Z test with the correlation between
AUROCs taken into account [14]. The calculating equa-
tion was ‘Z ¼ A1−A2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE1  SE1þ SE2  SE2‐2  r  SE1  SE2p ’ , ‘r’ was calcu-
lated manually according to the method described in the
published [14]. The equation ‘r = (rn + ra)/2’ was used, rn
indicates the Kendall tau correlation coefficient between
different diagnostic tools in the ‘no disease’ group, ra
indicates the Kendall tau correlation coefficient between
different diagnostic tools in the ‘disease’ group. SPSS 19.0
software (SPSS Inc., Chicago, IL) was used to perform all
the other analyses. A two-tailed P <0.05 was considered
statistically significant.
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Clinical characteristics according to glycometabolism
status by OGTT
There were 1,316 patients included in the present ana-
lysis and their average age was 62.4 years old and 63.3%
of them were male. Current smokers occupied 33% and
moderate to severe drinkers occupied 15.5%. The mean
systolic blood pressure was over 140 mmHg. More than
50% of the patients had a history of hypertension. The
mean levels of FPG and HbA1c were 5.7 mmol/L and
6.0%, respectively. The mean level of low-density lipopro-
tein was over 3.0 mmol/L.
The mean age, FPG, HbA1c, white cell counts, insulin
resistance index, and low-density lipoprotein were all
higher in the DM group than those in the prediabetes
and normoglycemia groups (all P < 0.05). The differences
of other variables among the groups were not statisti-
cally significant (see Additional file 1).
Detection of newly-diagnosed abnormal glycometabolic
status by HbA1c, FPG, and OGTT
The three tests identified different patients with abnormal
glycometabolic status among ischemic stroke patients
without previous DM (Table 1). There were 356 DM and
425 prediabetes cases categorized by OGTT. HbA1c iden-
tified 327 DM and 450 prediabetes cases, and FPG identi-
fied 188 DM and 333 prediabetes cases.
OGTT detected more patients with DM than HbA1c
(27.1% vs. 24.8%, P < 0.001), while HbA1c detected more
prediabetes than OGTT (34.2% vs. 32.3%, P < 0.001).
Among the three tests, FPG had the lowest detection rate
for DM (14.3%) and for prediabetes (25.3%), respectively.
The Venn diagrams illustrated the association among
the three tests (Figure 2). 102 DM (19.2%) and 48 predi-
abetes (5.7%) cases were concordantly detected by all
the three tests. HbA1c and OGTT concordantly detected
188 DM (38.0%) and 178 prediabetes (25.5%) patients.
HbA1c and FPG concordantly detected 123 DM (31.4%)
and 118 prediabetes (17.7%) patients.Table 1 Glycometabolic status categorized by HbA1c, FPG an
Total (n = 1,316) DM (n =
HbA1ca DM 327 188
Prediabetes 450 105
Normoglycemia 539 63
FPGb,c DM 188 130
Prediabetes 333 123
Normoglycemia 795 103
aand bindicate P < 0.05 when the glycometabolic status was compared with the dia
cindicates P < 0.05 when the glycometabolic status was compared with the diagnosis b
glucose.Comparison of the accuracy for diagnosing newly-diagnosed
abnormal glycometabolism between HbA1c/FPG and the
combined use (OGTT as the golden method)
Compared with HbA1c or FPG alone, the combination
of them increased the AUROC of diagnosing DM from
0.692 (HbA1c) and 0.652 (FPG) to 0.712 (the combination)
(AUC comparison between HbA1c and the combination,
Z = 1.78 < 1.96, P > 0.05; AUC comparison between FPG
and the combination, Z = 1.72 < 1.96, P > 0.05). Youden
index of the combination was higher than either of them
(Table 2).
In diagnosing prediabetes, HbA1c had a low to moder-
ate concordance with OGTT (AUROC:0.557, P = 0.001).
FPG had a poor concordance with OGTT for detecting
prediabetes (P = 0.388). The combination of HbA1c and
FPG had a slightly weak concordance with OGTT when
compared with HbA1c alone (AUROC: 0.557 vs. 0.554)
(Table 2). However, such a slight difference could not be
identified as statistically significant since the nonparamet-
ric Z test was not suitable (average Kendall tau correlation
coefficient = 0.52, average AUC was 0.556 (<0.700), the
correlation coefficient ‘r’ could not be looked up in Table I
of the Hanley et al. study [14], thus, Z value could not be
calculated).
The combination of HbA1c and FPG increased the
sensitivity of detecting DM to 60.7%, and also increased
the sensitivity of detecting prediabetes to 57.9% when
comparing HbA1c or FPG alone (Table 2).
In comparing the specificity of HbA1c or FPG alone
to the specificity of HbA1c and FPG combined for
detecting DM, the specificity remained high. However,
the specificity of detecting prediabetes when HbA1c and
FPG were combined use was decreased to 53%.
The combination of HbA1c and FPG increased sensitiv-
ity to 81.2% for detecting overall abnormal glycometabo-
lism when compared with either test, but the tradeoff was
to have a low specificity (48.8%). Therefore, combining the
two methods resulted in better diagnostic accuracy than
HbA1c alone, but worse than FPG alone (Table 2).d OGTT
OGTT








y HbA1c. HbA1c indicates glycated hemoglobin; FPG indicates fasting plasma
Figure 2 Venn Diagrams among HbA1c, FPG and OGTT for detecting newly-diagnosed abnormal glycometabolism. The figure was used
to illustrate the concordances and variances between the three methods of detecting the abnormal glycometabolism in acute ischemic stroke
patients without previous diabetes mellitus (IS without previous DM). DM: the newly-diagnosed diabetes mellitus patients. preDM: the newly-diagnosed
prediabetes patients. Number in bracket: the number of the patients. Box in grey: the total patients (n = 1316). Circle in green: the patient number of
DM or prediabetes detected by HbA1c. Circle in blue: the patient number of DM or prediabetes detected by FPG. Circle in red: the patient number of
DM or prediabetes detected by OGTT. HbA1c vs. FPG: the concordance diagnosed patients of DM or prediabetes detected by HbA1c and FPG. HbA1c
vs. OGTT: the concordance diagnosed patients of DM or prediabetes detected by HbA1c and OGTT. FPG vs. OGTT: the concordance diagnosed patients
of DM or prediabetes detected by FPG and OGTT.
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HbA1c for detecting abnormal glycometabolism
HbA1c was as a continuous variable entered into the
ROC analysis and OGTT remained as the reference index
(Table 3).
A value of HbA1c equal to 6.3% was found to be the
best cutoff value for detecting DM in our data based on
the Youden index (Youden index = 0.403 vs. 0.383 when
HbA1c = 6.3% vs. 6.5%).
A value of HbA1c equal to 5.9% was found to be the
ideal cutoff value for detecting prediabetes (Youden
index =0.332 vs. 0.296 as HbA1c ≥ 5.9% vs. ≥ 5.7%)
Discussion
As far as we know, only Huisa et al. has reported HbA1c
as a screening tool to detect a considerable diagnosticTable 2 HbA1c and FPG versus OGTT in diagnosing abnormal
AUROC Standard error 95% CI
HbA1c DM 0.692 0.018 0.657-0.
Prediabetes 0.557 0.017 0.523-0.
AGM 0.648 0.016 0.617-0.
FPG DM 0.652 0.019 0.616-0.
Prediabetes 0.515 0.017 0.481-0.
AGM 0.654 0.015 0.624-0.
HbA1c DM 0.712 0.017 0.678-0.
With FPG Prediabetes 0.554 0.017 0.521-0.
AGM 0.650 0.015 0.623-0.
HbA1c indicates glycated hemoglobin; FPG indicates fasting plasma glucose; OGTT
receiver operating characteristic curve; CI indicates confidence interval; AGM indicapercentage of abnormal glycometabolism among patients
with ischemic stroke, but it did not compare HbA1c with
other diagnostic tools and did not report ideal cutoff
values of HbA1c to identify DM and prediabetes [13]. The
present study found that the newly-diagnosed DM or
prediabetes by the three tests, HbA1c, FPG, and OGTT
among patients with acute ischemic stroke were not fully
concordant. The overlap between HbA1c and FPG,
HbA1c and OGTT, or the three was low respectively, as
all values were under 50%.
HbA1c, FPG, and the combination of them had different
diagnostic results in diagnosing DM or prediabetes, re-
spectively. HbA1c identified a higher diagnostic rate of
prediabetes than OGTT. HbA1c alone and FPG alone had
a low to moderate concordance with OGTT when diagnos-
ing DM, prediabetes, or overall abnormal glycometabolism.glycometabolic status
P Sensiti-vity Specif-icity Youden index
726 <0.001 0.528 0.855 0.383
590 0.001 0.419 0.695 0.114
678 <0.001 0.711 0.585 0.296
689 <0.001 0.365 0.940 0.305
548 0.388 0.273 0.756 0.029
684 <0.001 0.521 0.787 0.308
745 <0.001 0.607 0.817 0.424
587 0.001 0.579 0.530 0.109
681 <0.001 0.812 0.488 0.300
indicates oral glucose tolerance test; AUROC indicates the area under the
tes abnormal glucose metabolism.
Table 3 The Youden analysis for the HbA1c cut-off value of abnormal glycometabolism
Sensitivity Specificity Youden index HbA1c cut-off valuea
Diabetes mellitus 0.579 0.824 0.403 6.3%
Diabetes plus prediabetes 0.590 0.742 0.332 5.9%
aindicates the criteria lower limit of HbA1c for detecting prediabetes.
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cordant with OGTT in the diagnosis of prediabetes. When
compared with HbA1c or FPG alone, the combination of
HbA1c and FPG had the following results: 1) improved
diagnostic accuracy and sensitivity, with high specificity
persistence for diagnosing DM; 2) increased sensitivity but
decreased specificity for detecting the overall abnormal
glycometabolism; 3) did not enhance the diagnostic accur-
acy for prediabetes compared with HbA1c alone.
Diagnosis of DM
The detection rate of DM by HbA1c was higher than
that by FPG. This finding was inconsistent with other
studies [2]. This may be because FPG is more affected
by fluctuating glucose levels than HbA1c [3].
Although the diagnostic rate of DM identified by
HbA1c was lower than that by OGTT, which was in line
with other studies [9,15], HbA1c alone for diagnosing
DM was confirmed to be feasible in our study, which
was also confirmed by other studies although their study
populations were diverse with ours [16-18]. The combin-
ation of HbA1c and FPG significantly raised the diag-
nostic accuracy for DM compared with HbA1c or FPG
alone, which was also confirmed by Hjellestad et al. [8].
Although the difference between AUROC of HbA1c and
that of the combination of HbA1c and FPG was slight
and not statistically significant (Z = 1.78, P > 0.05), the
AUROC was indeed changed (AUROC changed from
0.692 to 0.712) and a much bigger sample size might
settle the puzzle.
Diagnosis of prediabetes
The detection rate of prediabetes by HbA1c was higher
than that by OGTT, which was in line with findings by
Hjellestad, et al. [8]. However, this was inconsistent with
Lorenzo et al. [19] and that from the National Health
and Nutrition Examination Survey [20]. Lorenzo, et al.
found that the HbA1c level of 5.7-6.4% had a low sensi-
tivity in detecting prediabetes because a large number of
prediabetes cases existed in clinical and epidemiological
settings, where a significant proportion of individuals
with HbA1c lower than 5.5% had either IFG or IGT.
Thus, they did not recommend HbA1c as a sole screen-
ing tool for prediabetes. Obesity, age, and race were also
elucidated in their studies, which influenced the results
of HbA1c as a diagnostic tool for prediabetes. These
differences could explain the different results between
these studies and our current research. Moreover, ourstudy patients as well as those in the study by Hjellestad,
et al. were both highly selective of chronic glycemic-
overload status, rather than the general population from
clinical or epidemiological settings. HbA1c can be indi-
cative of chronic hyperglycemia overload [21]. Lorenzo
et al. also noted that HbA1c has less precise correlates
of insulin resistance and secretion (the core of DM) than
FPG and PG2h (OGTT results) [19], which suggested
that insulin-resistance status was closely related to OGTT,
and compared with OGTT. HbA1c could provide more
other information, mainly chronic glycemia status (over-
load or not), in vivo rather than insulin-resistance status.
Thus, a lower detection rate of prediabetes and a higher
one of DM by OGTT, compared with those by HbA1c,
were presented in our study. The higher detection rate of
prediabetes by HbA1c might reflect a high chronic gly-
cemic overload in patients with ischemic stroke.
The FPG of 5.6-6.9 mmol/L had a statistically signifi-
cant discordance with OGTT, which may be because the
mean level of FPG in the OGTT-diagnosed prediabetes
arm was 5.4 mmol/l. This did not reach the lower limit
of the IFG range for detecting prediabetes. This may ex-
plain the slight decrease in diagnostic accuracy for predia-
betes when combining HbA1c and FPG.
Our results advocate the use of HbA1c as a screening
tool for the diagnosis of prediabetes. The combination of
HbA1c and FPG was not recommended as the first choice
in diagnosing prediabetes.
The ideal cutoff value of HbA1c for diagnosing DM and
abnormal glucose level
A cutoff value of HbA1c of 6.3% was found in our data
for diagnosing DM in our data, which is lower than that
recommended by ADA (6.5%). This was similar to the
reports from other studies [12,22]. The ideal cutoff value
of HbA1c of 5.9% for diagnosing the overall abnormal
glycometabolism in our study was slightly higher than
that recommended by ADA (5.7%) and is different with
that reported from Celik et al., (5.6%) [23]. The discrep-
ancy may be due to the different study populations.
Merits and limitations
The ACROSS-China study is a multi-central, nationwide
prospective cohort study. To our knowledge, it was the
first time that OGTT was nationwide used to detect
abnormal glucose among in-hospital patients with acute
stroke in China. However, OGTT was performed on the
14th day after stroke onset and patients might receive
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OGTT was used as the golden method in the present
study, the results might be affected. The present study
was only a cross-sectional study. The research methods
were not repeated to assess the reproducibility of the
findings. A much bigger sample size might improve the
comparison between the AUROCs to better differentiate
the diagnostic ability among these tools.
Conclusions
The present study found that the three tests (HbA1c,
FPG, and OGTT) identified different DM or prediabetes
patients in subjects with acute ischemic stroke. The over-
lap in diagnosing abnormal glycometabolism between
HbA1c and FPG, HbA1c and OGTT, or all three was low,
respectively. Combining HbA1c and FPG increased the
detection rate of DM, compared with OGTT. Our results
advocate the use of HbA1c as screening tool for the diag-
nosis of pre-diabetes.
Additional file
Additional file 1: Clinical characteristic of the three glycometabolism
statues according to OGTT results. This table describes the clinical
characteristics among the three abnormal glycometabolic profiles
diagnosed by OGTT. The mean age, FPG, HbA1c, white cell counts, insulin
resistance index, and low-density lipoprotein were all higher in the DM
group (P < 0.05 in comparison among the three groups). The differences of
other variables among the groups were not statistically significant. The
variables were compared through one-way analysis of variance, test χ2 or
Fisher’s exact test. A two-tailed P <0.05 was considered statistically
significant.
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